SequelSEC

TG THERAPEUTICS, INC. TGTX

Pharmaceutical Preparations · CIK 0001001316 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$799.54M
Fiscal year ended 2026-06-30
Operating income
$136.33M
Fiscal year ended 2026-06-30
Free cash flow
$17.38M
Fiscal year ended 2026-06-30

TG THERAPEUTICS, INC. (TGTX) reported revenue of $799.54M and net income of $441.49M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TG THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

TG THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$799.54M
Cost of revenue$140.94M
Gross profit$658.60M
Operating income$136.33M
Net income$441.49M
Research & development$225.80M
Weighted-average diluted sharesUnavailable
Pretax income$101.60M
Income tax expense-$339.89M
Diluted EPSUnavailable
Selling, general & administrative$296.46M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

TG THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$482.58M
Total assets$1.64B
Current assets$1.15B
Total liabilities$1.04B
Current liabilities$268.49M
Total equity incl. NCI$604.08M
Temporary (mezzanine) equityUnavailable
Inventory$147.97M
Accounts receivable$401.56M
GoodwillUnavailable
Long-term debt$745.39M
Accounts payableUnavailable

Cash flow

TG THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$17.88M
Capital expenditures$491.00K
Investing cash flow$21.89M
Financing cash flow$313.73M
Net change in cash$353.50M
Stock-based compensation$81.16M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$123.00K

Derived

TG THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$17.38M
Gross margin82.4%
Operating margin17.1%
FCF margin2.2%
SBC / revenue10.2%
Current ratio4.27x
Revenue YoY growth76.1%
Net margin55.2%
R&D / revenue28.2%
CapEx / revenue0.1%
Long-term debt / equity1.23x
Effective tax rate-334.5%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TGTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.